Two new Alzheimer’s drugs show no clinical benefit in patients

R. I.

Madrid

Updated:

Keep

Gantenerumab and solanezumab, two investigational drugs for the prevention of Alzheimer’s disease, have failed to demonstrate a significant impact in cognitive decline in people with dominant inheritance Alzheimer’s disease (DIAD) in a phase 2/3 clinical trial published in “Nature Medicine.”

However, gantenerumab did reduce molecular markers of the disease and slowed neurodegeneration in the brain, although without demonstrating evidence of cognitive benefit.

These results have prompted researchers to offer the drug gantenerumab participants as part of an outreach, and changes in Alzheimer’s disease continue to be monitored in those participants who are receiving the drug.

The heredity Alzheimer’s dominant is a shape

READ  The virus that affects 80% of sexually active people and can cause cancer of the cervix, penis or anus

Leave a Reply

Your email address will not be published. Required fields are marked *